Alkermes (NASDAQ:ALKS) Price Target Raised to $50.00 at Needham & Company LLC

Alkermes (NASDAQ:ALKS - Get Free Report) had its target price boosted by equities research analysts at Needham & Company LLC from $45.00 to $50.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a "buy" rating on the stock. Needham & Company LLC's price objective would suggest a potential upside of 37.93% from the stock's previous close.

Several other analysts have also commented on the stock. Piper Sandler reduced their price target on shares of Alkermes from $45.00 to $43.00 and set an "overweight" rating on the stock in a research report on Tuesday, March 24th. Bank of America lifted their target price on shares of Alkermes from $34.00 to $36.00 and gave the company a "neutral" rating in a report on Thursday, April 9th. Truist Financial upgraded shares of Alkermes to a "strong-buy" rating in a report on Wednesday, March 25th. Wells Fargo & Company boosted their price target on shares of Alkermes from $37.00 to $43.00 and gave the stock an "overweight" rating in a research note on Thursday, February 26th. Finally, Royal Bank Of Canada decreased their price target on shares of Alkermes from $47.00 to $45.00 and set an "outperform" rating for the company in a research note on Thursday, February 26th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $44.71.

Alkermes Trading Up 6.1%

ALKS stock opened at $36.25 on Wednesday. The company has a market cap of $6.03 billion, a price-to-earnings ratio of 25.35 and a beta of 0.31. Alkermes has a 12 month low of $25.17 and a 12 month high of $36.56. The firm has a 50-day moving average of $31.53 and a two-hundred day moving average of $30.98.

Alkermes (NASDAQ:ALKS - Get Free Report) last released its quarterly earnings data on Saturday, February 14th. The company reported $0.29 EPS for the quarter. The company had revenue of $384.55 million during the quarter. Alkermes had a net margin of 16.37% and a return on equity of 14.91%. As a group, equities analysts forecast that Alkermes will post -0.69 earnings per share for the current year.

Insider Activity at Alkermes

In other news, EVP Craig C. Hopkinson sold 9,000 shares of the company's stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $33.40, for a total value of $300,600.00. Following the completion of the sale, the executive vice president directly owned 81,389 shares of the company's stock, valued at approximately $2,718,392.60. This represents a 9.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP David Joseph Gaffin sold 2,034 shares of the company's stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $33.20, for a total transaction of $67,528.80. Following the completion of the sale, the executive vice president directly owned 231,558 shares of the company's stock, valued at $7,687,725.60. The trade was a 0.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 39,102 shares of company stock valued at $1,265,090 over the last ninety days. Insiders own 4.59% of the company's stock.

Institutional Investors Weigh In On Alkermes

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Royal Bank of Canada raised its holdings in Alkermes by 117.2% during the first quarter. Royal Bank of Canada now owns 275,526 shares of the company's stock worth $9,098,000 after purchasing an additional 148,696 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new position in Alkermes during the first quarter worth about $213,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Alkermes by 4.3% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 482,332 shares of the company's stock worth $15,927,000 after purchasing an additional 20,091 shares in the last quarter. Cetera Investment Advisers raised its holdings in Alkermes by 32.3% during the second quarter. Cetera Investment Advisers now owns 13,907 shares of the company's stock worth $398,000 after purchasing an additional 3,394 shares in the last quarter. Finally, Quantbot Technologies LP raised its holdings in Alkermes by 539.4% during the second quarter. Quantbot Technologies LP now owns 6,976 shares of the company's stock worth $200,000 after purchasing an additional 5,885 shares in the last quarter. 95.21% of the stock is owned by hedge funds and other institutional investors.

Alkermes News Summary

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Q1 results beat expectations — Alkermes reported ($0.43) EPS vs. the consensus loss of ($0.57) and revenue of $392.9M vs. $363.3M expected; revenue was up ~28% year‑over‑year, supporting the stock move higher. Alkermes Q1 Earnings Release
• Positive Sentiment: Management highlighted LUMRYZ momentum on the earnings call as a key driver of commercial growth and reiterated product-level traction that underpins near‑term revenue strength. Alkermes Earnings Call: LUMRYZ Momentum Drives Growth
• Neutral Sentiment: The full earnings‑call transcript is available for investors who want line‑by‑line detail on guidance, cost drivers and commercial commentary. Useful for modeling assumptions and Q&A takeaways. Alkermes Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Analyst/metric notes: Zacks and others highlight the beats on revenue and EPS and provide comparisons vs. estimates and year‑ago metrics — helpful context but largely reiterates reported results. ALKS Q1: Key Metrics vs Estimates (Zacks)
• Neutral Sentiment: Insider activity: an EVP sold ~2,034 shares under a pre‑arranged 10b5‑1 plan; small percentage impact and not an unusual liquidity event but worth noting. Insider Sale: David Joseph Gaffin
• Negative Sentiment: FY‑2026 guidance disappointed vs. consensus — Alkermes narrowed EPS guidance to roughly ($0.521)–($0.405), materially below the street's ~($0.09) estimate; revenue guidance was trimmed to ~$1.7–1.8B (vs. consensus near $1.8B). This guidance gap is the main downside risk to the rally and may pressure forward estimates. Alkermes Reports First Quarter 2026 Financial Results

About Alkermes

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes' portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes' commercial franchise features several approved products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.